Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Review of Schwarz’s Neupro Shaped By Parkinson’s Pharmacovigilance

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

FDA’s review of the Schwarz Neupro (rotigotine) NDA illustrates the important role pharmacovigilance has come to play in the agency’s consideration of new Parkinson’s disease treatments.

You may also be interested in...

Restless Leg Syndrome Market Prepares To Move As GSK, UCB Advance Drugs

UCB could bring the first competitor to GlaxoSmithKline's Requip (ropinirole) for restless leg syndrome to market later this year after submitting an sNDA for Neupro (rotigotine) for RLS

Renal Effect Seen In Neupro Lab Values, But Not Robust Enough For Label

Data supporting an FDA safety reviewer's concerns that laboratory value changes seen in Neupro studies could indicate an effect on renal function were found insufficiently robust for inclusion in labeling by supervisory reviewers, FDA documents show

Neupro Clinical Development

Neupro Clinical Development




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts